• The liver is a principle site for biotransformation. Liver cell functional reduction results in reduced conjugation capacity, prolonging the stay time of reactive metabolites in the body and adding more oxidative stress burden on liver tissues.
• Formulation targets: providing substrates (cysteine, glycine) for glutathione biosynthesis; activation of the Nrf2 pathway to stimulate expression of GST and NQO1; choleretic effect for bile flow and micelle formation for lipophilic conjugates; membrane protection of hepatocytes; and mitochondrial compartment protection from lipid peroxidation.
• Active compounds: silybin-phosphatidylcholine complexes [6], preparations containing glucoraphanin for sulforaphane production, choline, betaine, taurine, selenium and standardized Cynara scolymus caffeoylquinic acid preparations.
• Claim anchor: Choline provides an EU-authorized claim on “Maintenance of normal liver function” at certain consumption levels. It is a reliable way of obtaining an EU liver function claim; that’s why choline is present in FRL hepatic formulations at claim-bearing dosages.

• The gastrointestinal tract serves as the final route of excretion for biliary conjugates. When gut transit is slow, or there is an imbalance in gut flora, β-glucuronidase action of bacteria in the colon deconjugates the glucuronide and leads to reabsorption of the aglycone through enterohepatic recirculation, thereby sending the parent compound back into systemic circulation, negating any conjugation done upstream. [3,4,5]
• Formulation focus: transit time and stool consistency; faecal bulk and water-holding capacity; short-chain fatty acids, especially butyrate, as the preferred colonocyte fuel source; tight-junction stability; and modulation of bacteria producing β-glucuronidase.
• Typical ingredients: psyllium husk and other highly viscous soluble fibres, inulin and fructo-oligosaccharides from chicory root, galacto-oligosaccharides, partially hydrolysed guar gum, resistant starch, and defined-strain Lactobacillus and Bifidobacterium strains with genome-sequenced and collection-deposit identification.
• Claim basis: wheat bran fibre and chicory inulin each has authorised European claims for effects on bowel function at certain daily amounts [7,8,9,10]. These daily amounts are quite large — 10 g and 12 g respectively – and should dictate the format choice even more than other considerations. A 3 g sachet cannot support a chicory inulin claim, and that fact should shape the brief on day one.

• The skin plays a minor role in xenobiotic detoxification but responds directly to the systemic burden of oxidative and inflammatory stress. This is the point where ingestible and topicals meet and where the question of which category it belongs in becomes a regulatory choice before becoming a formulation choice.
• Ingestible targets: dermal antioxidant capacity, deposition of carotenoids and tocopherols in stratum corneum, collagen matrix substrate via hydrolyzed collagen peptides with vitamin C as a cofactor for hydroxylation of prolyl and lysyl residues, and dermal microcirculation.
• Topical ingredient targets include: replenishment of barrier lipids, epidermal antioxidant loading, and chelation of catalytic transition metal ions in the formulation base to prevent lipid peroxidation of the skin. Delivery system technology includes liposomes and niosomal carriers, lipid nanoparticles, and cyclodextrins.
• Claim anchor: vitamin C has an authorized EU claim for normal collagen formation, which is important for normal function of skin. Biotin, niacin, and zinc have claims for maintenance of normal skin function. Polyphenols tell the botanical story; the nutrient tells the claim story.

“Cosmeceutical” is a market term, not a regulatory category

• In the United States, a product is either a cosmetic or a drug under the FD&C Act; there is no intermediate class, and the Modernization of Cosmetics Regulation Act (MoCRA) now adds facility registration, product listing, safety-substantiation records and serious adverse event reporting obligations.
• In the EU, Regulation (EC) 1223/2009 requires a Responsible Person, a Cosmetic Product Safety Report and CPNP notification. China regulates under CSAR with NMPA registration or filing depending on function. ASEAN applies to the ASEAN Cosmetic Directive.
• FRL scopes the category question at kick-off, because a claim that is acceptable on an ingestible in one market can convert a topical into a drug in another.

• Steroid hormone metabolites are eliminated via the same hepatic conjugation processes as xenobiotics. Oestrogens are hydroxylated to 2-hydroxy and 16α-hydroxy metabolites by CYP1A1 and CYP1B1 activity, methylated by COMT activity, and glucuronidated by UGT activity before elimination via the bile and urine excretion [12].
• Formulation targets: facilitating the 2-hydroxylation pathway, provision of sufficient methylation co-factors (vitamins B12 and folate, magnesium for COMT function), glucuronidation, and minimizing colonic deconjugation and reabsorption through fibre and microbiome modification.
• Examples of active ingredients: glucosinolate-derived indole-3-carbinol and diindolylmethane, calcium D-glucarate [11], sulforaphane precursors, lignan-rich flax seed extracts, and B vitamin co-factor complexes.
• This is the highest risk claim area in this category, and the copy shows it – it revolves around metabolite elimination and co-factors, without naming a clinical condition. Folate, vitamins B12 and magnesium have authorised EU claims that can be applied here; the botanicals cannot.

• Elevated oxidative load and increased intestinal permeability contribute to low-grade systemic inflammatory tone. The formulation objective is the normalisation of inflammatory signalling and antioxidant status, not the inhibition of a pathological condition.
• Mechanical levers: NF-κB pathway regulation, NLRP3 inflammasome signalling, resolution phase mediators via long-chain omega-3s, and reduced endotoxin transfer via barrier function. Traceable endpoints are high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), faecal calprotectin and LBP — measured in clinical trials, never put on pack.
• Claim anchor: Vitamin C, vitamin D, zinc and selenium have EU-approved immune function claims. These make up the regulatory underpinning of any detox SKU with immune positioning.

• Mitochondria serve as both sources and targets for reactive oxygen species (ROS). Inefficient operation of the electron transport chain (ETC) leads to superoxide leakage, damage to mitochondrial DNA and cardiolipin, as well as to decreased ATP generation per substrate molecule.
• Formulation focuses areas: electron carrier balance, mitochondrial antioxidants, fatty acid transport into the mitochondrial matrix, and PGC-1α-dependent biogenesis. Active ingredients: Coenzyme Q10 in ubiquinol and solubilized forms; alpha-lipoic acid; L-carnitine and acetyl-L-carnitine; riboflavin; vitamins from niacin family (precursors of NAD+) and magnesium.
• Claims basis: riboflavin, niacin, vitamin B6, vitamin B12, vitamin C, magnesium, iron and pantothenic acid have authorized EU claims for “contribution to normal energy-yielding metabolism” and “reduction of tiredness and fatigue”. These are wordings that carry “restores energy” claims in the category where “restores energy” wording is prohibited.